ILIllumina ILMN · NASDAQ
$262.66 +0.05% (+$0.12)
- Market cap
- $39.7B
- Enterprise value
- $41.1B
- P/E
- 48.1x
- Forward P/E
- 47.4x
- PEG
- -
- P/S
- 8.8x
- P/FCF
- 42.2x
- EV/EBITDA
- 30.2x
- ROIC
- 13.5%
- Gross margin
- 66.8%
- Net margin
- 18.4%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- 1.1x
- Beta
- 1.42
- Free float
- 99.7%
About the company
Illumina Inc. (ILMN) is an American biotechnology company specializing in the development and production of DNA sequencing and genetic analysis systems. With innovative products and technologies such as the NovaSeq sequencer, Illumina enables researchers and clinicians to conduct advanced genetic studies and diagnostics. The company is known for its emphasis on innovation and research, allowing it to continuously improve its products and expand the possibilities of genetic research. Illumina also collaborates with academic and industrial partners to develop new applications for genetic analysis. Illumina Inc. (ILMN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on genetics and innovations in DNA sequencing.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Jacob Thaysen
Employees
8,600
Headquarters
San Diego
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number